Comprehensive medication guide to Farxiga including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$100 copay per month for most commercial insurance plans; commercially insured patients may pay $0 using the AstraZeneca Farxiga SavingsRx Card (max $175 savings/fill). Medicare Part D plans cover Farxiga — Tier 2–3 typically; Medicare Part D price negotiation applies in 2026.
Estimated Cash Pricing
Brand-name Farxiga retails for approximately $590–$778 per 30-day supply without insurance; with a GoodRx coupon, it can be as low as $288. Generic dapagliflozin (FDA-approved April 2026) is available starting around $330–$617, and prices are expected to decrease as generic competition increases.
Medfinder Findability Score
85/100
Summarize with AI
On this page
Farxiga is the brand name for dapagliflozin, a once-daily oral medication made by AstraZeneca. It belongs to a class of drugs called SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors). First FDA-approved on January 8, 2014, Farxiga has expanded its approvals over the years to address three distinct conditions: type 2 diabetes mellitus, heart failure, and chronic kidney disease.
In April 2026, the FDA approved the first generic versions of dapagliflozin, making this medication available from multiple manufacturers. Farxiga is available as 5 mg and 10 mg film-coated tablets. It is not a controlled substance and can be prescribed by any licensed healthcare provider.
FDA-approved indications include: (1) adjunct to diet and exercise to improve glycemic control in adults and children aged 10 years and older with type 2 diabetes; (2) to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure; and (3) to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and HF hospitalization in adults with CKD at risk of progression.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Farxiga works by inhibiting the SGLT2 protein in the proximal tubules of the kidney. SGLT2 is responsible for reabsorbing approximately 90% of filtered glucose back into the bloodstream. By blocking SGLT2, dapagliflozin allows excess glucose to pass into the urine rather than returning to the blood — lowering blood sugar through an insulin-independent mechanism.
SGLT2 also regulates sodium reabsorption. Farxiga's sodium-excreting effects produce an osmotic diuresis (increased urination with water loss) and natriuresis (sodium excretion) — reducing fluid overload and cardiac preload in patients with heart failure. This mechanism explains Farxiga's benefits across multiple organ systems and why it helps patients with or without diabetes.
In the kidneys, Farxiga reduces glomerular hyperfiltration — the excessive pressure inside the kidney's filtering units that accelerates CKD progression — lowers blood pressure, and may exert direct anti-inflammatory and anti-fibrotic effects on renal tissue. These combined actions make dapagliflozin one of the few medications proven to benefit the heart, kidneys, and glucose control simultaneously.
5 mg — tablet
Starting dose for type 2 diabetes in adults and children ≥10 years; taken once daily with or without food
10 mg — tablet
Standard dose for heart failure and CKD; may be used for T2DM when additional glycemic control is needed; taken once daily
Farxiga is generally well-stocked at major pharmacy chains and is not listed on the FDA's drug shortage database in 2026. The April 2026 FDA approval of generic dapagliflozin from multiple manufacturers has further increased overall supply. Most patients with commercial insurance or cash-pay can access Farxiga at large chain pharmacies (CVS, Walgreens, Walmart, Rite Aid) without significant delays.
However, some patients do encounter barriers: insurance prior authorization delays (especially for CKD and HF indications), step therapy policies requiring Jardiance first, and occasional stock gaps at smaller or lower-volume pharmacies. Cost is also a significant barrier for uninsured patients, given the $590–$778 retail price for brand Farxiga. The availability of generic dapagliflozin is expected to reduce both cost and access barriers over time.
If you're struggling to find Farxiga at your local pharmacy, medfinder can call pharmacies near you on your behalf to find which ones have it in stock, saving you time and frustration.
Farxiga (dapagliflozin) is not a controlled substance and has no special DEA prescription requirements. Any licensed prescriber with prescribing authority can write a prescription for Farxiga. Because it treats multiple conditions, prescribers from several specialties commonly prescribe it:
Primary Care Physicians (PCPs) — most common prescribers for T2DM indication
Endocrinologists — for complex or poorly controlled T2DM
Cardiologists — for heart failure and cardiovascular risk reduction
Nephrologists — for chronic kidney disease management
Nurse Practitioners (NPs) and Physician Assistants (PAs) — across all applicable specialties
Geriatricians — for elderly patients with diabetes and cardiovascular risk
Farxiga can also be prescribed through telehealth platforms. Because it is a non-controlled medication, it can be prescribed via video or phone consultations without in-person DEA restrictions. Diabetes-focused telehealth services, cardiology virtual care platforms, and nephrology telehealth programs all regularly prescribe dapagliflozin for eligible patients with established diagnoses.
No. Farxiga (dapagliflozin) is not a controlled substance. It is not classified under any DEA schedule (I through V). This means it can be prescribed by any licensed healthcare provider — including primary care doctors, nurse practitioners, physician assistants, and telehealth providers — without special DEA registration requirements.
Because Farxiga is not controlled, prescriptions can include multiple refills, and the medication can be filled at any licensed pharmacy without quantity or refill restrictions that apply to scheduled substances. Patients can also receive Farxiga through mail-order pharmacies and telehealth-affiliated pharmacy services. There are no restrictions on how much supply can be dispensed at a time, and 90-day prescriptions are routinely written for stable patients.
The most common side effects reported in Farxiga clinical trials (occurring in ≥2% of patients) include:
Female genital mycotic infections (vaginal yeast infections)
Urinary tract infections (UTIs)
Nasopharyngitis (upper respiratory symptoms, runny nose)
Increased urination (polyuria)
Back pain
Modest weight loss (~6 lbs over 24 weeks)
Diabetic ketoacidosis (DKA): Can occur at near-normal blood sugars (euglycemic DKA). Symptoms: nausea, vomiting, abdominal pain, difficulty breathing, fruity breath.
Volume depletion / dehydration: Dizziness, low blood pressure, lightheadedness — especially with loop diuretics or in the elderly.
Urosepsis / pyelonephritis: Fever, chills, flank pain with UTI symptoms — emergency care required.
Necrotizing fasciitis (Fournier's gangrene): Rare but life-threatening. Perigenital pain, redness, swelling — emergency surgery required.
Hypoglycemia: Primarily when combined with insulin or sulfonylureas.
Allergic reactions / anaphylaxis: Hives, swelling, difficulty breathing — stop medication and seek emergency care.
Acute kidney injury: Decreased urination, leg swelling — report to doctor immediately.
Know what you need? Skip the search.
Jardiance (empagliflozin)
Most closely comparable SGLT2 inhibitor; FDA-approved for T2DM, HF, and CKD; strong cardiovascular mortality data (EMPA-REG); currently brand-only, 10-25 mg daily
Invokana (canagliflozin)
First FDA-approved SGLT2 inhibitor (2013); approved for T2DM, CV risk reduction, and CKD with T2DM; carries boxed warning for lower limb amputation risk; brand-only
Steglatro (ertugliflozin)
SGLT2 inhibitor for T2DM only; not FDA-approved for HF or CKD; limited cardiovascular trial data; 5-15 mg once daily
Brenzavvy (bexagliflozin)
Newer SGLT2 inhibitor for type 2 diabetes; 20 mg once daily; less long-term trial data than Farxiga or Jardiance; generally available
Prefer Farxiga? We can find it.
Insulin (all types)
moderateAdditive glucose-lowering increases hypoglycemia risk. Reduce insulin dose when adding Farxiga; monitor blood sugar closely.
Sulfonylureas (glipizide, glimepiride, glyburide)
moderatePharmacodynamic synergism increases hypoglycemia risk. Consider dose reduction of sulfonylurea when combining.
Loop and thiazide diuretics
moderateAdditive diuretic effect increases risk of dehydration, hypotension, and acute kidney injury. Monitor fluid status and kidney function.
NSAIDs (ibuprofen, naproxen, celecoxib)
moderateIncreased risk of acute kidney injury when combined with Farxiga's volume-depleting effects. Avoid prolonged NSAID use; prefer acetaminophen.
Rifampin (UGT1A9 inducer)
moderateMay reduce dapagliflozin plasma levels by increasing its metabolism, potentially reducing efficacy.
GLP-1 receptor agonists (semaglutide, dulaglutide)
minorAdditive blood sugar lowering; generally well tolerated but monitor glycemic control when initiating or stopping.
ACE inhibitors / ARBs
minorCombination is common and often beneficial for CKD/HF. Additive blood pressure lowering — monitor for hypotension on initiation.
Farxiga (dapagliflozin) is one of the most clinically significant medications of the past decade — a drug that has transformed the standard of care for type 2 diabetes, heart failure, and chronic kidney disease. Its unique kidney-based mechanism produces benefits across multiple organ systems, making it a cornerstone of modern cardiorenal-metabolic therapy.
The April 2026 FDA approval of generic dapagliflozin marks a new chapter for access — more supply, more competition, and ultimately lower prices for patients. This development, combined with AstraZeneca's savings programs, makes Farxiga more accessible than ever for commercially insured patients. Medicare patients should confirm their Part D plan's current formulary tier and copay for 2026.
If you're having trouble finding Farxiga or generic dapagliflozin at a pharmacy near you, medfinder calls pharmacies in your area to find which ones have your medication in stock — saving you time and ensuring you stay on your treatment plan without interruption.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini